Vera Therapeutics (VERA) Assets Average (2021 - 2026)

Vera Therapeutics' Assets Average history runs 6 years deep, the most recent figure standing at $678.2 million for Q1 2026.

• Quarterly Assets Average rose 7.16% year-over-year to $678.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $678.2 million (up 7.16% YoY) and the FY2025 annual result came in at $695.2 million, up 67.27% from the prior year.
• Assets Average was $678.2 million for Q1 2026 at Vera Therapeutics, up from $626.1 million in the prior quarter.
• Across five years, Assets Average topped out at $678.2 million in Q1 2026 and bottomed at $124.4 million in Q1 2022.
• A 5-year average of $351.0 million and a median of $297.5 million in 2024 frame the typical range for Assets Average.
• Annual changes were most pronounced in 2024 — Assets Average surged 191.67% — and 2026, when it increased 7.16%.
• Vera Therapeutics' Assets Average stood at $131.4 million in 2022, then jumped by 33.62% to $175.6 million in 2023, then jumped by 191.67% to $512.1 million in 2024, then advanced by 22.26% to $626.1 million in 2025, then grew by 8.32% to $678.2 million in 2026.
• Business Quant data shows VERA's Assets Average at $678.2 million in Q1 2026, $626.1 million in Q4 2025, and $548.0 million in Q3 2025.